News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
719,521 Results
Type
Article (42534)
Company Profile (294)
Press Release (676693)
Multimedia
Podcasts (81)
Webinars (12)
Section
Business (210473)
Career Advice (2092)
Deals (36634)
Drug Delivery (107)
Drug Development (83062)
Employer Resources (175)
FDA (16586)
Job Trends (15417)
News (356106)
Policy (33929)
Tag
Academia (2598)
Accelerated approval (5)
Adcomms (21)
Allergies (92)
Alliances (51450)
ALS (97)
Alzheimer's disease (1402)
Antibody-drug conjugate (ADC) (140)
Approvals (16582)
Artificial intelligence (277)
Autoimmune disease (24)
Automation (16)
Bankruptcy (371)
Best Places to Work (11770)
BIOSECURE Act (20)
Biosimilars (112)
Biotechnology (188)
Bladder cancer (78)
Brain cancer (29)
Breast cancer (293)
Cancer (2346)
Cardiovascular disease (188)
Career advice (1753)
Career pathing (31)
CAR-T (155)
Cell therapy (440)
Cervical cancer (20)
Clinical research (67622)
Collaboration (877)
Company closure (2)
Compensation (564)
Complete response letters (25)
COVID-19 (2663)
CRISPR (47)
C-suite (257)
Cystic fibrosis (105)
Data (2313)
Decentralized trials (2)
Denatured (29)
Depression (47)
Diabetes (279)
Diagnostics (6463)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (124)
Drug pricing (115)
Drug shortages (28)
Duchenne muscular dystrophy (97)
Earnings (88686)
Editorial (41)
Employer branding (21)
Employer resources (149)
Events (115502)
Executive appointments (753)
FDA (17971)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (775)
Gene editing (116)
Generative AI (21)
Gene therapy (325)
GLP-1 (757)
Government (4550)
Grass and pollen (5)
Guidances (150)
Healthcare (19002)
Huntington's disease (25)
IgA nephropathy (28)
Immunology and inflammation (131)
Indications (30)
Infectious disease (2808)
Inflammatory bowel disease (147)
Inflation Reduction Act (8)
Influenza (52)
Intellectual property (99)
Interviews (323)
IPO (16800)
IRA (47)
Job creations (4060)
Job search strategy (1492)
Kidney cancer (10)
Labor market (43)
Layoffs (499)
Leadership (18)
Legal (8380)
Liver cancer (77)
Lung cancer (326)
Lymphoma (158)
Machine learning (9)
Management (59)
Manufacturing (338)
MASH (75)
Medical device (13468)
Medtech (13473)
Mergers & acquisitions (20398)
Metabolic disorders (726)
Multiple sclerosis (82)
NASH (17)
Neurodegenerative disease (96)
Neuropsychiatric disorders (29)
Neuroscience (1971)
NextGen: Class of 2025 (6637)
Non-profit (4528)
Now hiring (40)
Obesity (386)
Opinion (229)
Ovarian cancer (81)
Pain (103)
Pancreatic cancer (89)
Parkinson's disease (152)
Partnered (21)
Patents (247)
Patient recruitment (116)
Peanut (49)
People (59321)
Pharmaceutical (91)
Pharmacy benefit managers (20)
Phase I (20973)
Phase II (29759)
Phase III (22291)
Pipeline (1358)
Policy (159)
Postmarket research (2654)
Preclinical (8941)
Press Release (68)
Prostate cancer (108)
Psychedelics (31)
Radiopharmaceuticals (251)
Rare diseases (402)
Real estate (6258)
Recruiting (67)
Regulatory (23187)
Reports (47)
Research institute (2369)
Resumes & cover letters (358)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (78)
Series A (134)
Series B (88)
Service/supplier (12)
Sickle cell disease (55)
Special edition (17)
Spinal muscular atrophy (150)
Sponsored (30)
Startups (3729)
State (2)
Stomach cancer (14)
Supply chain (69)
Tariffs (52)
The Weekly (50)
Vaccines (718)
Venture capitalists (42)
Weight loss (255)
Women's health (36)
Worklife (16)
Date
Today (32)
Last 7 days (940)
Last 30 days (3041)
Last 365 days (32888)
2025 (11861)
2024 (35770)
2023 (40630)
2022 (51797)
2021 (56329)
2020 (54791)
2019 (47397)
2018 (35770)
2017 (33137)
2016 (32662)
2015 (38615)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (781)
Alabama (54)
Alaska (7)
Arizona (240)
Arkansas (14)
Asia (40762)
Australia (6527)
California (6405)
Canada (2074)
China (549)
Colorado (274)
Connecticut (279)
Delaware (159)
Europe (87089)
Florida (950)
Georgia (212)
Idaho (57)
Illinois (559)
India (26)
Indiana (327)
Iowa (11)
Japan (175)
Kansas (106)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (927)
Massachusetts (4796)
Michigan (225)
Minnesota (403)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (67)
New Hampshire (63)
New Jersey (1800)
New Mexico (29)
New York (1806)
North Carolina (1006)
North Dakota (8)
Northern California (2812)
Ohio (208)
Oklahoma (14)
Oregon (39)
Pennsylvania (1428)
Puerto Rico (13)
Rhode Island (33)
South America (1163)
South Carolina (25)
South Dakota (1)
Southern California (2411)
Tennessee (105)
Texas (954)
United States (24106)
Utah (190)
Virginia (160)
Washington D.C. (64)
Washington State (570)
West Virginia (3)
Wisconsin (59)
719,521 Results for "semnur pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025
March 10, 2025
·
7 min read
Press Releases
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali
November 7, 2024
·
13 min read
Press Releases
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion
October 16, 2024
·
13 min read
Press Releases
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from November 7, 2024 to January 28, 2025
December 30, 2024
·
7 min read
Press Releases
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination, Providing for a Pre-Transaction Equity Value of Semnur of $2.5 Billion
September 3, 2024
·
17 min read
Press Releases
Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary
October 28, 2024
·
14 min read
Business
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination
July 3, 2024
·
20 min read
Press Releases
Apimeds Pharmaceuticals US, Inc. Announces Pricing of Initial Public Offering
May 8, 2025
·
5 min read
Press Releases
Nika Pharmaceuticals, Inc. (NIKA) Latest Developments
April 14, 2025
·
2 min read
Press Releases
Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025
January 21, 2025
·
6 min read
1 of 71,953
Next
